Polyclonal antibody preparation that depletes T lymphocytes for induction immunosuppression.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity and Fc-mediated ADCC, with additional T-cell apoptosis and functional inhibition, producing potent immunosuppression.
YES
DIRECT
ATG contains polyclonal IgG that binds CD18 (LFA-1β) on T cells; bound antibody triggers complement-dependent lysis and Fc-mediated ADCC, and can also induce apoptosis, directly depleting the target cells.
Intravenous anti-CD20 monoclonal antibody that depletes B cells via antibody-dependent cellular cytotoxicity, complement activation, and apoptosis.
Chimeric anti‑CD20 monoclonal antibody that binds CD20 on B cells and depletes CD20+ malignant and normal B cells via antibody‑dependent cellular cytotoxicity, complement‑dependent cytotoxicity, antibody‑dependent phagocytosis, and induction of apoptosis.
YES
DIRECT
Anti-CD20 binding triggers Fc-mediated ADCC by NK cells/macrophages, complement-dependent lysis (CDC), antibody-dependent phagocytosis, and can induce apoptosis of CD20+ B cells.
An anti-CD79b antibody-drug conjugate that delivers the microtubule-disrupting payload MMAE to CD79b-positive malignant B cells, causing apoptosis.
Anti‑CD79b monoclonal antibody linked via a cleavable linker to MMAE. After binding CD79b on B cells and internalization, MMAE is released to inhibit tubulin polymerization, causing G2/M arrest and apoptosis in CD79b‑positive malignant B cells.
YES
DIRECT
The ADC binds CD79b on B cells, is internalized, and releases MMAE via linker cleavage; MMAE inhibits tubulin polymerization, causing G2/M arrest and apoptosis of CD79b-expressing cells.
An anti-CD79b antibody-drug conjugate that delivers the microtubule-disrupting payload MMAE to CD79b-positive malignant B cells, causing apoptosis.
Anti‑CD79b monoclonal antibody linked via a cleavable linker to MMAE. After binding CD79b on B cells and internalization, MMAE is released to inhibit tubulin polymerization, causing G2/M arrest and apoptosis in CD79b‑positive malignant B cells.
NO
INDIRECT
Polatuzumab vedotin binds CD79b on B cells, is internalized, and releases MMAE, which binds beta-tubulin (vinca site) to inhibit microtubule polymerization, causing G2/M arrest and apoptosis in CD79b-positive cells; tubulin expression alone is not targeted.
A chimeric anti-CD20 monoclonal antibody that depletes B cells via ADCC, complement activation, and direct induction of apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B lymphocytes and depletes CD20+ cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and direct induction of apoptosis.
YES
DIRECT
Binds CD20 on B cells and induces killing via antibody-dependent cellular cytotoxicity (FcγR-mediated), complement-dependent cytotoxicity, and direct induction of apoptosis.